Photo: drdavidherediav.com
Jul 15, 2025, 15:15
David Heredia: Long-term Data from the VISION Trial
David Heredia, Head of Oncology Department at Punta Médica Hospital, shared a post on X:
“Long-term data from the VISION trial shows:
Tepotinib offers durable responses in METex14 skipping NSCLC.
- ORR: 51–57%
- PFS: ~6–8.5 months
- OS: ~20–22 months
- Liquid biopsy effective for detection”
Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer
Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara, Jr, Emmanuel Adewusi, Xiuning Le
You can read the Full Article on Cancer Treatment Reviews.
More posts featuring David Heredia on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 15, 2025, 15:15
Jul 15, 2025, 15:10
Jul 15, 2025, 14:55
Jul 15, 2025, 14:52
Jul 15, 2025, 14:26
Jul 15, 2025, 13:54
Jul 15, 2025, 13:40
Jul 15, 2025, 13:20
Jul 15, 2025, 12:47
Jul 15, 2025, 10:49